Advertisements

Regeneron Licenses Weight Loss Drug as Bluebird Bio Goes Private

by Daisy

Regeneron Pharmaceuticals has taken new steps to expand its work in obesity treatment by licensing a weight loss drug and sharing study results for two drugs aimed at preserving muscle mass. These efforts are part of the company’s broader plan to address health problems related to obesity.

In separate news, two biotech firms focused on neuroscience, Atai Life Sciences and Alto Neuroscience, announced new partnerships. Their goal is to advance brain-related treatments and develop therapies for mental health conditions.

Advertisements

Additionally, Bluebird Bio completed its transition from a publicly traded company to a private one. This change marks a major shift in how the company operates.

Advertisements

Related Topics:

Advertisements

Flow Athletic Cofounder Ben Lucas Lost 25kg By Diet

Woman Unrecognisable After Six Stone Weight Loss

Common Diet Brits Use To Lose Weight May Lead To Depression Study Finds

You may also like

blank

Your go-to fitness resource, offering customized workout plans, nutrition guidance, and expert wellness advice. Committed to empowering all fitness levels with cutting-edge tools, reliable content, and a holistic approach to achieving health and vitality.

【Contact us: [email protected]

Copyright © 2023 Gtehy.com